Alpha 1 Biomedicals, SciClone deal

SCLN acquired worldwide rights to ALBM's Zadaxin immunomodulator, which it previously had licensed from ALBM. SCLN will no longer pay royalties to ALBM. SCLN paid $1.93 million, consisting of $130,00...